AMX-883

Key Takeaways

• AMX-883 targets BRD9 via DCAF16, a novel E3 ligase recruiter.
• Oral administration enables potential outpatient AML treatment.
• Preclinical data show selective degradation of BRD9 in AML cells.
• Design repurposed a known BRD9 binder to improve potency.
• Amphista plans IND submission within the next year.

Pulse Analysis

BRD9, a member of the bromodomain‑containing protein family, regulates chromatin remodeling and transcriptional programs that sustain leukemic stem cells. In acute myeloid leukemia, overexpression of BRD9 drives proliferative signaling and resistance to conventional agents, making it an attractive therapeutic target. Traditional inhibitors have struggled with selectivity and on‑target toxicity, prompting a shift toward targeted protein degradation, which can eradicate the protein entirely rather than merely blocking its activity.

Molecular‑glue degraders have emerged as a powerful modality, co‑opting cellular E3 ubiquitin ligases to tag disease‑relevant proteins for destruction. AMX-883 distinguishes itself by recruiting DCAF16, an understudied ligase that offers a complementary substrate profile to the more common CRBN and VHL recruiters. The oral formulation further differentiates the candidate, potentially allowing chronic outpatient dosing—a critical advantage in a disease where patients often endure intensive inpatient chemotherapy cycles.

If Amphista’s IND filing proceeds on schedule and clinical data confirm the preclinical promise, AMX-883 could reshape the AML therapeutic landscape. An effective, oral BRD9 degrader would not only address a high‑unmet‑need segment but also validate DCAF16 as a viable ligase for future drug‑discovery programs. Investors and competitors alike will watch the upcoming trials closely, as success could accelerate the broader adoption of DCAF16‑based molecular glues across oncology and beyond.